Invivyd (NASDAQ: IVVD)
Invivyd Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Invivyd Company Info
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
News & Analysis
Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?
The clinical-stage biotech delivered positive trial results for its new COVID-19 preventative antibody treatment.
Why Shares of Invivyd Jumped This Week
The company's shares have climbed along since an FDA announcement earlier this week.
Why Adagio Therapeutics Stock Is Soaring Today
Investors are reacting to better than expected clinical trial results for its COVID-19 treatment candidate.
These 2 Nasdaq Biotech Stocks Are Soaring Wednesday Morning
Markets looked to take a breather after a huge surge in recent weeks.
Why Shares of Adagio Therapeutics Soared 25.9% on Thursday
The clinical-stage biotech company is working on an antiviral treatment to fight multiple variants of COVID-19.
Should Adagio Say Goodbye to Its COVID-19 Hopes?
The prospects for Adagio's experimental COVID antibody therapy appear to be bleak.
Why Adagio Therapeutics Stock Dived by 13% Today
Another analyst gets notably less bullish on the company's prospects.
Why Adagio Therapeutics Stock Is Falling Again Today
You can always count on investment bank analysts to yell fire after a biotech's lead program goes up in flames.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.